Observation on efficacy of tirofiban in patients with ischemic progressive stroke

NIU Wen-shu; LIU Yang; WANG Yu-bin; NING Qun; LI Zhi-yun

doi:10.16462/j.cnki.zhjbkz.2019.04.024

Volume 23 Issue 4

Apr. 2019

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2019 > 23(4): 489-492

NIU Wen-shu, LIU Yang, WANG Yu-bin, NING Qun, LI Zhi-yun. Observation on efficacy of tirofiban in patients with ischemic progressive stroke[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(4): 489-492. doi: 10.16462/j.cnki.zhjbkz.2019.04.024

Citation:

NIU Wen-shu, LIU Yang, WANG Yu-bin, NING Qun, LI Zhi-yun. Observation on efficacy of tirofiban in patients with ischemic progressive stroke[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2019, 23(4): 489-492. doi: 10.16462/j.cnki.zhjbkz.2019.04.024

Citation:

PDF( 794 KB)

Observation on efficacy of tirofiban in patients with ischemic progressive stroke

doi: 10.16462/j.cnki.zhjbkz.2019.04.024

Department of Clinical Neurology, 988 th Hospital of People's Liberation Army, Zhengzhou 450007, China

More Information

Corresponding author: WANG Yu-bin, E-mail: wsniu@163.com
Received Date: 2018-10-26
Rev Recd Date: 2019-01-26
Publish Date: 2019-04-10

Abstract

Abstract

Objective To observe the efficacy of tirofiban in the treatment of ischemic progressive stroke. Methods 300 patients who met the diagnostic criteria of ischemic progressive stroke were divided into the control group and tirofiban group. Patients in the control group received treatment of PA2S regiment, i.e., a combination of aspirin, clopidogrel, probucol and atorvastatin. Patients in the tirofiban group received extra tirofiban on the basis of PA2S therapy. National institute of health stroke scale (NIHSS) score was evaluated on patients in both group before the therapy and 3 days, 1 month, 6 months after the therapy respectively. Results For the control group, the average NIHSS score was 11.3±4.2, 11.5±4.4, 8.8±4.1, 6.1±4.1 before therapy and at 3 days, 1 month, 6 months after the therapy. And for the tirofiban group, the average NIHSS score was 11.4±3.9, 10.8±3.6, 7.4±3.2, 4.4±3.0 at the corresponding period respectively. There were statistical differences between the two groups in the period of 1 month and 6 months after treatment with P < 0.001. Conclusions Tirofiban hydrochloride can improve the degree of neurological deficit and outcome in patients with ischemic progressive stroke.
- Progressive stroke,
- Tirofiban,
- Curative effect

FullText(HTML)

References(10)

References

[1]	张宇, 汤颍, 王红, 等. 大动脉粥样硬化型急性缺血性脑卒中患者入院后首个24小时内血压变异与出院结局[J]. 中华疾病控制杂志, 2018, 22(8): 776-780. DOI: 10.16462/j.cnki.zhjbkz.2018.08.004. Zhang Y, Tang Y, Wang H, et al. Blood pressure variability within the first 24 hours after admission and discharge outcome in acute ischemic stroke patients with large-arteryatherosclerosis[J]. Chin J Dis Control Prev, 2018, 22(8): 776-780. DOI: 10.16462/j.cnki.zhjbkz.2018.08.004.
[2]	李娟, 黄东辉, 王冲, 等. 辽宁省农村地区2013年脑卒中早死所致的疾病负担分析[J]. 中华疾病控制杂志, 2017, 21(3): 255-260. DOI: 10.16462/j.cnki.zhjbkz.2017.03.010. Li J, Huang DH, Wang C, et al. Analysis of the disease burden of stroke-related deaths among rural areas of Liaoning Province in 2013[J]. Chin J Dis Control Prev, 2017, 21(3): 255-260. DOI: 10.16462/j.cnki.zhjbkz.2017.03.010.
[3]	徐淑华, 孙静, 钱金明, 等. 脑卒中高危人群知信行调查及其影响因素分析[J]. 中华疾病控制杂志, 2017, 21(8): 857-859. DOI:10.16462/j.cnki.zhjbkz.2017. 08.025. Xu SH, Sun J, Qian JM, et al. Investigation and analysis of KAP among high risk population of stroke[J]. Chin J Dis Control Prev, 2017, 21(8): 857-859. DOI:10.16462/j.cnki.zhjbkz.2017. 08.025.
[4]	Del BA, Palumbo V, Lamassa M, et al. Progressive lacunar stroke: Review of mechanisms, prognostic features, and putative treatments[J]. Int J Stroke, 2012, 7(4): 321-329. DOI: 10.1111/j.1747-4949.2012.00789.x
[5]	Januzzi JL, Jr., Snapinn SM, DiBattiste PM, et al. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (prism-plus) trial[J]. Circulation, 2002, 105(20): 2361-2366. doi: 10.1161/01.CIR.0000016359.94919.16
[6]	Siebler M, Hennerici MG, Schneider D, et al. Safety of tirofiban in acute ischemic stroke: The satis trial[J]. Stroke, 2011, 42(9): 2388-2392. DOI: 10.1161/STROKEAHA.110.599662
[7]	Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of tirofiban, a nonpeptide gpiib/iiia platelet receptor antagonist in progressive stroke: An open pilot study[J]. Cerebrovasc Dis, 2001, 12(4): 308-312. DOI: 10.1159/000047726
[8]	Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment[J]. Stroke, 1993, 24(1): 35-41. doi: 10.1161/01.STR.24.1.35
[9]	Meyer BC, Hemmen TM, Jackson CM, et al. Modified national institutes of health stroke scale for use in stroke clinical trials: Prospective reliability and validity[J]. Stroke, 2002, 33(5): 1261-1266. doi: 10.1161/01.STR.0000015625.87603.A7
[10]	Torgano G, Zecca B, Monzani V, et al. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: A double-blind randomized trial[J]. Cerebrovasc Dis, 2010, 29(3): 275-281. DOI: 10.1159/000275503.